+Compare
ALRN
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
8.89M

ALRN Aileron Therapeutics Forecast, Technical & Fundamental Analysis

a developer of stapled peptide drugs

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ALRN with price predictions
07:00 PM EST Nov 30, 2023

ALRN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ALRN turned positive on November 01, 2023. Looking at past instances where ALRN's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2023. You may want to consider a long position or call options on ALRN as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

ALRN moved above its 50-day moving average on November 06, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ALRN crossed bullishly above the 50-day moving average on November 14, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ALRN advanced for three days, in of 211 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 133 cases where ALRN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALRN broke above its upper Bollinger Band on November 30, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.829) is normal, around the industry mean (20.645). P/E Ratio (0.135) is within average values for comparable stocks, (137.274). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.009).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 27%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 173%. For the same stocks of the Industry, the average monthly volume growth was -7% and the average quarterly volume growth was 52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of stapled peptide drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
285 Summer Street
Phone
+1 617 995-0900
Employees
6
Web
https://www.aileronrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRI70.312.12
+3.11%
Carter's
GDDY102.011.95
+1.95%
GoDaddy
EU3.910.01
+0.26%
enCore Energy Corp
MIMO0.12N/A
-0.80%
Airspan Networks Holdings
TZOO9.98-0.17
-1.67%
Travelzoo

ALRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALRN has been loosely correlated with KZIA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ALRN jumps, then KZIA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALRN
1D Price
Change %
ALRN100%
+16.98%
KZIA - ALRN
35%
Loosely correlated
-16.18%
JSPR - ALRN
33%
Loosely correlated
+0.83%
BIOR - ALRN
31%
Poorly correlated
+7.26%
KRRO - ALRN
30%
Poorly correlated
+16.92%
TMBR - ALRN
27%
Poorly correlated
N/A
More

Groups containing ALRN

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALRN
1D Price
Change %
ALRN100%
+16.98%
drugs
(undefined stocks)
23%
Poorly correlated
+2.08%
pharmaceuticals
(undefined stocks)
17%
Poorly correlated
+1.82%